Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

References

• Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(Suppl 1):9–20.
   PubMedGoogle Scholar
• Ghoreschi K, Laurence A, Yang XP, et al. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 2011;32:395–401.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092–1102.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79–88.
   PubMed Web of Science ®Google Scholar
• AbuHilal M, Walsh S, Shear N. The role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis. J Cutan Med Surg. 2016;20:509–516.
   PubMed Web of Science ®Google Scholar
• Chen Y, Qian T, Zhang D, et al. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy. 2015;7:1023–1037.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–776.
   PubMed Web of Science ®Google Scholar
• Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18:156–169.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15:311–316.
   PubMedGoogle Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75:329–338.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–9 e9.
   PubMed Web of Science ®Google Scholar
• Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3:5–29.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76:70–80.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–493.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–1090.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36 e1.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018;32:e32–e4.
   PubMed Web of Science ®Google Scholar
• Magnano M, Loi C, Patrizi A, et al. Secukinumab in multi-failure psoriatic patients: the last hope?. J Dermatolog Treat. 2018;1–3.
   PubMed Web of Science ®Google Scholar
• Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017;30:e12550.
   PubMed Web of Science ®Google Scholar
• Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
   PubMed Web of Science ®Google Scholar
• Araujo NM. Hepatitis B virus intergenotypic recombinants worldwide: an overview. Infect Genet Evol. 2015;36:500–510.
   PubMed Web of Science ®Google Scholar
• Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32:e120–e1.
   PubMed Web of Science ®Google Scholar
• Yanagihara S, Sugita K, Yoshida Y, et al. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27:185–186.
   PubMed Web of Science ®Google Scholar
• Yang C, Cui F, Chen LM, et al. Correlation between Th17 and nTreg cell frequencies and the stages of progression in chronic hepatitis B. Mol Med Rep. 2016;13:853–859.
   PubMed Web of Science ®Google Scholar
• Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014;105(Suppl 1):34–40.
   PubMedGoogle Scholar
• Bedair AA, Darwazeh AM, Al-Aboosi MM. Oral Candida colonization and candidiasis in patients with psoriasis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:610–615.
   PubMed Web of Science ®Google Scholar
• Picciani BL, Michalski-Santos B, Carneiro S, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013;68:986–991.
   PubMed Web of Science ®Google Scholar
• Taheri Sarvtin M, Shokohi T, Hajheydari Z, et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53:e555–e560.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47–62.
   PubMed Web of Science ®Google Scholar